OraSure Technologies Inc
OSUROraSure Technologies Inc is a biotechnology company specializing in the development, manufacture, and distribution of point-of-care diagnostic tests and sample collection devices. It is known for its focus on infectious disease testing, including HIV, hepatitis, and COVID-19, as well as other health screening and diagnostic solutions. The company's products are used in both healthcare settings and for at-home testing.
Company News
Following the WHO's declaration of a Public Health Emergency for the Bundibugyo virus Ebola outbreak on May 17, 2026, biodefense diagnostics companies are experiencing significant capital inflows. Co-Diagnostics is positioned as a strategic play due to its decentralized manufacturing network through joint ventures in India (CoSara) and Saudi Arab...
OraSure Technologies reported Q1 2026 revenue of $27.9 million (4% sequential growth) with diagnostics revenue up 12% sequentially. The company achieved gross margin expansion to 42.3% GAAP and 43.4% non-GAAP through manufacturing insourcing. Despite operating losses of $23.3 million GAAP, the company maintains $177 million in cash with no debt. ...
OraSure Technologies announced the appointment of John D. Bertrand, a healthcare technology executive with AI-enabled diagnostics expertise, to its Board of Directors. The company will seek shareholder approval to declassify its Board at the 2026 Annual Meeting. Following constructive engagement, OraSure entered into a Cooperation Agreement with ...
The global drug screening market is projected to reach USD 20.86 billion by 2031, growing at a CAGR of 16.16%. Chromatography and mass spectrometry technologies dominated with 44.77% market share in 2025. Asia-Pacific is the fastest-growing region, driven by expanding healthcare infrastructure and workplace safety initiatives. Market growth is fu...
A comprehensive market research report on over-the-counter and direct-to-consumer infectious disease diagnostics forecasts significant growth through 2029, driven by rapid testing technologies, privacy concerns, and digital accessibility. The report analyzes market trends across 15 countries, covering respiratory, STD, UTI, and other infectious d...
